US: industry skeptical of new US drug safety bill despite record recalls

Additional drug safety responsibilities could be placed on pharmaceutical companies with the introduction of a new US bill in the Senate. The bill, which comes in the wake of record product recalls, aims to strengthen manufacturing standards and better equip the FDA to oversee the pharmaceutical supply chain. However, if passed, the legislation would create considerable costs for drug makers.

News Release - July 22, 2010
Evolution Summit 2010 Summit 2010
Fairmont Le Montreux Palace, Montreux, Switzerland, 27 - 29 October 2010
http://www.evolution-summit.com/FarmavitaPR

Interview with: Maha Al Farhan, President & Chief Executive Officer, ClinArt

Maha Al Farhan from ClinArt, a sponsor at the marcus evans Evolution Summit 2010, shares her thoughts on overcoming reporting challenges through better communication.

Reporting information to health authorities in an accurate and timely manner is a top priority, as well as a challenge, for Chief Medical Officers (CMOs) of clinical trials. When patient health is at risk, no chances can be taken. CMOs can ease the reporting process by establishing healthy communication channels between the different parties, and making use of innovative software solutions, says Maha Al Farhan, President and Chief Executive Officer at ClinArt. From a sponsor company at the marcus evans Evolution Summit 2010 taking place in Switzerland, 27 - 29 October, Al Farhan discusses reporting best practices, and healthy communication strategies.

Sydney, Australia, July 30, 2010

GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article based on its proprietary patent intelligence for Aricept® (Donepezil), the world's best selling anti-Alzheimer's drug developed by Eisai and co-marketed with Pfizer. The article analyses the patent landscape surrounding Donepezil, highlighting the need for comprehensive patent information in the development of launch strategies for generic products to minimise the risk of litigation.

The Multi-Dimensional Challenges of Market Access

Gerard Klop from Vintura, a sponsor at the marcus evans PharmaBrand Summit 2010, discusses how best to tackle the market access issues facing pharmaceutical companies today.

Monte-Carlo, Monaco, June 21, 2010 

The name of the game is early stakeholder involvement and internal and external collaboration, says Gerard Klop, Managing Partner at Vintura. Pharmaceutical marketing directors must look for capabilities inside and outside their organisation, as the industry has shifted to a multi- stakeholder, channel and proposition environment, and become very dynamic in nature. Solving everything within their own department would not address the multi-dimensional aspects of the problem, would take too much time to develop and would not create the flexibility to adapt quickly to the ever changing environment. As a sponsor at the marcus evans PharmaBrand Summit 2010, taking place in Monaco, 21 - 23 June, Klop highlights why adopting collaborative models is the way to go.

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

APA 2010: unmet needs in major depressive disorder remain key

Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.

ASCO 2010: ipilimumab achieves breakthrough in 'long dark tunnel' of metastatic melanoma

At this year's American Society of Clinical Oncology meeting, Bristol-Myers Squibb presented data for its monoclonal antibody ipilimumab in metastatic melanoma. Research and development in this area has been underwhelming over the past few years and, despite its high rate of adverse events, ipilimumab represents a breakthrough in the treatment of metastatic melanoma.

Menzies Consulting, Inc. Publishes Article on Using Editorial Calendars

How-To Article Teaches C-Level Execs to Value Industry Media